I am very sure that there will be a buy offer soon from big pharmaceutical company
garygillgary1
Posts
-
-
$11 on Monday for sure!!
-
They should change the name from GPAK to Gindia to get more investor because no one in this world to see the name of Pakistan
-
Useless CEO
-
It will hit $7 soon !!
-
Cathie Wood-led ARK Investment Management bought a massive stake in digital media player-maker Roku Inc (NASDAQ:ROKU) on Thursday following its quarterly earnings release.
Funds operated by ARK bought over 215,000 shares of Roku at an estimated valuation of over $12 million based on Thursday's closing price. The purchase was done via the flagship ARK Innovation ETF (NYSE:ARKK), the ARK Next Generation Internet ETF (NYSE:ARKW) and the ARK Fintech Innovation ETF (NYSE:ARKF).
-
Roku Stock (NASDAQ:ROKU), Analyst Ratings, Price Targets, Predictions
Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.Consensus Rating1
Buy
Highest Price Target1
$150.00
Lowest Price Target1
$30.00
Consensus Price Target1
$102.47
Analyst Rating Summary1
Buy Overweight Hold Underweight Sell 12 3 7 1 3 -
Inhibikase Therapeutics Stock (NASDAQ:IKT), Analyst Ratings, Price Targets, Predictions
Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.Consensus Rating1
Hold
Highest Price Target1
$5.00
Lowest Price Target1
$5.00
Consensus Price Target1
$2.50 -
$2 plus by next week
-
Dare Bioscience Stock (NASDAQ:DARE), Analyst Ratings, Price Targets, Predictions
Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.Consensus Rating1
Buy
Highest Price Target1
$11.00
Lowest Price Target1
$6.00
Consensus Price Target1
$7.88
Analyst Rating Summary1
Buy Overweight Hold Underweight Sell 4 0 0 0 0
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JonesTrading
Roth Capital
Brookline Capital1calculated from analyst ratings published within the last 3 years
ANALYST RATINGS FOR DARE BIOSCIENCE
All Ratings (7)
Upgrades (0)
Downgrades (0)
Initiations (3)
Premium Tools & IdeasDate
Upside/Downside
Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/31/2023 621.28% HC Wainwright & Co. → $7 Reiterates → Buy Get Alert
12/13/2022 621.28% HC Wainwright & Co. $6 → $7 Maintains Buy Get Alert
12/01/2022 518.24% JonesTrading → $6 Initiates → Buy Get Alert
04/01/2022 518.24% HC Wainwright & Co. $5 → $6 Maintains Buy Get Alert
06/30/2021 1033.44% Roth Capital $9 → $11 Maintains Buy Get Alert
12/18/2020 415.2% HC Wainwright & Co. → $5 Initiates → Buy Get Alert
04/28/2020 672.8% Brookline Capital -
Analyst Forecast
According to 12 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is $6.12, which is an increase of 530.86% from the latest price.Price Target
$6.12
(530.86% upside)
Analyst Consensus: BuyStrongSell
Sell
Hold
Buy
StrongBuy
0
5
10 -
Is dare will get any benefit from abortion pill ban ?
-
Ad-Supported Disney+ Plan Now Available On Roku Devices, Four Months After Initial Launch' - The Streamable
Mentioned: DIS ROKU
https://thestreamable.com/news/ad-supported-disney-plus-plan-now-available-on-roku-devices-four-months-after-initial-launchDid Disney and Roku sit down and hammer out an agreement over advertising revenue splits? Or did someone at the House of Mouse wish upon a star to make their dreams come true? Either way, Roku has announced that the ad-supported Disney+ tier â known as Disney+ Basic â is finally available to all users of its streaming devices.
The rollout of Disney+ Basic on Roku puts an end to a four-month absence for Disney's ad-supported subscriber plans on the leading streaming platform in the United States. Neither the service by itself nor any iterations of the Disney Bundle (which adds in Hulu and ESPN+ at a discount) that offered Basic were available. The Streamable noted when Disney+ Basic was launched in December, and reached out to Disney for more clarification regarding its unavailability on Roku platforms.
'We remain committed to working with Roku and reaching an agreement that is fair and advantageous to both parties, giving their users more choice and flexibility,' a Disney spokesperson said at the time.
-
Accomplishments:
License Agreement with Organon to Commercialize XACIATOTM
Ovaprene IDE Approval for Pivotal Contraceptive Efficacy Study
Positive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1
Three Additional Portfolio Programs (DARE-PDM1, DARE-GML and grant-funded DARE-LBT)
2023 Anticipated Milestones:XACIATO First Commercial Sale
Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Topline Data
Ovaprene Pivotal Contraceptive Efficacy Study Initiaton
DARE-PDM1 Phase 1 Study Topline Data
IND and Clinical Study Initiation Activities for DARE-VVA1 and DARE-HRT1
SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2022 and provided a company update.“Daré announced a number of positive developments related to our existing portfolio since the beginning of 2022 which serve to benefit all of our stakeholders. We entered into an exclusive global license agreement with Organon for commercialization of our first FDA-approved product, XACIATO. We completed two Phase 1/2 clinical studies in Australia and announced positive topline data for both. We received FDA approval of our IDE application for Ovaprene, allowing us to conduct a single arm, open-label pivotal contraceptive efficacy study and we hosted an investigator meeting. Finally, we completed subject screening for our exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% for female sexual arousal disorder and are targeting the second quarter of 2023 to announce topline data. We seek to continue the progress made over the past fifteen months by moving these candidates forward in development in 2023 and 2024,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
-
Analyst Forecast
According to 12 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is $6.12, which is an increase of 494.18% from the latest price.Price Target
$6.12
(494.18% upside)
Analyst Consensus: BuyStrongSell
Sell
Hold
Buy
StrongBuy
0
5
10 -
The projected fair value for Roku is US$103 based on 2 Stage Free Cash Flow to Equity
Roku's US$61.71 share price signals that it might be 40% undervalued
The US$71.75 analyst price target for ROKU is 30% less than our estimate of fair value
In this article we are going to estimate the intrinsic value of Roku, Inc. (NASDAQ:ROKU) by taking the expected future cash flows and discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex.Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
-
Analyst Forecast
According to 6 analysts, the average rating for ONCS stock is "Sell." The 12-month stock price forecast is $5.1, which is an increase of 150.00% from the latest price.Price Target
$5.1
(150.00% upside)
Analyst Consensus: SellStrongSell
Sell
Hold
Buy
StrongBuy
0
2
4 -
Xaciato is a Vaginal Anti-infectives class drug manufactured by ORGANON. The average counter price of Xaciato is $202.99 per 1, 5GM of 2% Gel, but you can pay only $151.22 for 1, 5gm of 2% Tube of generic Xaciato with a SingleCare prescription drug discount card to use the generic Xaciato coupon.
https://www.singlecare.com › xaciato
Xaciato Coupons 2023: Up to 80% Discount - SingleCare -
Why This Roku Analyst Is Double Upgrading The Streaming Stock
Mentioned: ROKU
Shares of Roku Inc (NASDAQ: ROKU) climbed in premarket trading on Friday, after the company reported an earnings beat.The San Jose, California-based company is outperforming the broader advertising market, according to BofA Securities.
The Analyst: Ruplu Bhattacharya upgraded the rating for Roku from Underperform to Buy, while raising the price target from $45 to $85.
-
B of A Securities Upgrades Roku to Buy, Raises Price Target to $85
Mentioned: ROKU
B of A Securities analyst Ruplu Bhattacharya upgrades Roku (NASDAQ:ROKU) from Underperform to Buy and raises the price target from $45 to $85.Latest Ratings for ROKU DateFirmActionFromTo
Feb 2022Morgan StanleyMaintainsUnderweight Feb 2022BenchmarkMaintainsBuy Feb 2022GuggenheimMaintainsBuy
DARE
F
GPAK
DARE
DBTX
ROKU
ROKU
IKT
TKLF
DARE
DARE
DARE
ROKU
DARE
DARE
ROKU
ONCS
DARE
ROKU
ROKU